SeraCare Life Sciences Presents Data Supporting the Development of New Diagnostic Control Products at Clinical Virology Symposium

SeraCare Life Sciences, Inc. (NASDAQ: SRLS) today announced three presentations at the Clinical Virology Symposium held April 19-22, 2009 in Daytona Beach, FL based on scientific data generated in the Company’s research programs. These data support SeraCare’s plans to expand their diagnostic controls product portfolio later this year with a new genotype panel for human papillomavirus, the virus that can lead to cervical cancer, and a suite of quality controls to support testing for the sexually transmitted diseases (STDs) chlamydia and gonorrhea.

"Testing for STDs is the largest and fastest growing segment of molecular diagnostics today and, given SeraCare’s longstanding expertise in the development of quality controls, we intend to play a leadership role in this area,” said Susan Vogt, President and Chief Executive Officer of SeraCare. "SeraCare has focused its scientific efforts on high-value areas that will drive the introduction of a number of new offerings in 2009, including those in the STD arena. These new products will not only play an important role in the accurate testing and treatment of multiple diseases, but also will also support the Company’s near-term goal of achieving and sustaining enhanced cash flow and operating profitability.”

Posters presented by SeraCare scientists Dr. Bharathi Anekella, Dr. Renee Howell and Dr. Patricia Garrett at the Clinical Virology Symposium included:

• "Development of an HPV Genotype Panel for Evaluation of Multiple Test Platforms”
• "Platform Specific Quality Controls for Nucleic Acid Tests for Chlamydai Trachomatis (CT) and Neisseria Gonorrheae (NG)”
• "20 Years of Research and Development Experience with HIV, HCV and HBV Seroconversion Panels”

About SeraCare Life Sciences:

SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, validation and production of human diagnostics and therapeutics. SeraCare’s innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. SeraCare's quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry.

Forward-Looking Statement:

This press release contains disclosures that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about SeraCare Life Sciences, Inc. ("SeraCare" or the "Company"). All statements regarding our expected future financial position, results of operations, cash flows, dividends, financing plans, business strategy, budget, projected costs or cost savings, capital expenditures, competitive positions, growth opportunities for existing products or products under development, plans and objectives of management for future operations and markets for stock are forward-looking statements. In addition, forward-looking statements include statements in which we use words such as "expect," "believe," "anticipate," "intend," or similar expressions. Although we believe the expectations reflected in such forward-looking statements are based on reasonable assumptions, we cannot assure you that these expectations will prove to have been correct, and actual results may differ materially from those reflected in the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this press release include, but are not limited to, failure to maintain proper inventory levels, availability of financing, covenant limitations in our existing credit facility, reductions or terminations of government or other contracts, interruption in our supply of products or raw materials, actions of SeraCare's competitors and changes in the regulatory environment. Many of these factors are beyond our ability to control or predict.